Identification of Proteomic Subtypes with Differential Responses to Immune Checkpoint Inhibition in Cutaneous Melanoma
Year: 2026
Type: article
Abstract: PURPOSE: Predictive biomarkers for combined PD-1/CTLA-4 blockade in metastatic melanoma remain limited. We analyzed pretreatment proteogenomic data to define response and resistance biology. EXPERIMENTAL DESIGN: We profiled 208 pretreatment FFPE specimens from patients with metastatic cutaneous melanoma treated across 12 institutions, including 164 receiving dual PD-1+CTLA-4 blockade (Discovery, n=97; Validation 1, n=67) and 44 receiving PD-1 monotherapy. Tumors underwent TMT-based proteomics, RNA sequencing, and targeted/low-pass whole-genome sequencing. Pathway clustering, survival modeling, deconvolution, and machine-learning classification defined and validated subtype signatures. RESULTS: Proteomic pathway clustering identified three reproducible ICI subtypes: immune-enriched ICI-sensitive, ribosome-high, and EMT-like/stromal-enriched. Subtypes stratified progression-free survival after dual ICI in the Discovery (P=0.01) and Validation 1 cohorts (P=0.02). The ICI-sensitive subtype had the highest responder fraction (74% and 73%), compared with ribosome-high (67% and 60%) and EMT-like tumors (44% and 43%) in the Discovery and Validation 1 cohorts, respectively. Subtype-outcome associations were consistent with previous immunotherapy datasets, with pooled hazard ratios ≈0.5-0.8 for immune-enriched tumors. Subtypes plus clinical variables predicted 3-year progression/death better than clinical variables alone in Validation 1 (AUC 0.80 vs 0.64). A 127-protein classifier recapitulated subtype membership in Validation 1 (AUC 0.89-0.97) and predicted 3-year progression/death with AUC 0.79. Subtypes reflected distinct immune, translational, and stromal/ECM programs and nominated POLR3A-associated biology as a candidate resistance axis. CONCLUSIONS: Proteomic pathway states define reproducible, biologically interpretable melanoma subtypes associated with differential benefit from dual PD-1/CTLA-4 blockade. A clinically tractable 127-protein classifier provides a foundation for prospective biomarker-driven combination immunotherapy trials.
Source: Clinical Cancer Research
Authors: Shrabanti Chowdhury, Kourosh Abdollahi, Francesca Petralia, Jacob J. Kennedy, Jianhui Gong, Weiping Ma, Richard G. Ivey, Rose C. Pletcher, Azra Krek, Ata S. Moshiri, Zachary T. Herbert, Travis D. Lorentzen, Yan-Chak Li, Yi Hsiao, Anna Xing, Nicole Tignor, Jeffrey R. Whiteaker, Antonella Bacchiocchi, Mehdi Mesri, Jeffrey E. Gershenwald, Victor G. Prieto, Alexander J. Lazar, Ryan J. Sullivan, Genevieve M. Boland, Tara C. Mitchell, Giorgos Karakousis, Douglas B. Johnson, Ruth Halaban, Georgina V. Long, Richard A. Scolyer, Iman Osman, Paul W. Harms, Kelly L. Harms, Charlotte E. Ariyan, Piotr Rutkowski, Anna M. Czarnecka, Anna Szumera-Ciećkiewicz, Dirk Schadendorf, Anne Zaremba, Marcus Bosenberg, John M. Kirkwood, Mario Sznol, Jedd D. Wolchok, Tao Liu, Marcin P. Cieslik, Pei Wang, Diwakar Davar, Amanda G. Paulovich
Institutions: Icahn School of Medicine at Mount Sinai, Fred Hutch Cancer Center, University of Michigan, New York University, Dana-Farber Cancer Institute, Yale University, National Cancer Institute, The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, University of Pennsylvania, Vanderbilt University Medical Center, Melanoma Institute Australia, Memorial Sloan Kettering Cancer Center, The Maria Sklodowska-Curie National Research Institute of Oncology, Essen University Hospital, University of Pittsburgh Medical Center, Weill Cornell Medicine, Pacific Northwest National Laboratory
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funders: Bristol-Myers Squibb, Melanoma Research Alliance, Fred Hutchinson Cancer Research Center, University of Washington, Tizona Therapeutics, National Institutes of Health, University of Texas MD Anderson Cancer Center, National Health and Medical Research Council, National Cancer Institute, Office of Research Infrastructure Programs, National Institutes of Health
OpenAlex ID: W7235707608
